Nan Fung Group Holdings’s Rubius Therapeutics, Inc RUBY Stock Holding History

Nan Fung Group Holdings’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-56,768	Closed	-$313K	–	47
2022 Q1	$313K	Hold	56,768	–	–	0.15%	35
2021 Q4	$550K	Hold	56,768	–	–	0.16%	34
2021 Q3	$1.01M	Hold	56,768	–	–	0.32%	22
2021 Q2	$1.39M	Buy	+56,768	New	+$1.42M	0.43%	19

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AFM

Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nan Fung Group Holdings's RUBY Position: Q2 2022 in Review

Nan Fung Group Holdings sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 56,768 shares — an estimated $313K sold.

Nan Fung Group Holdings first reported a position in RUBY in Q2 2021 and held it in 4 quarters. The position peaked at $1.39M in Q2 2021. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

Nan Fung Group Holdings reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
Nan Fung Group Holdings sold 56,768 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $313K.
Nan Fung Group Holdings first reported a position in Rubius Therapeutics, Inc in Q2 2021 and held it in 4 quarters.
Nan Fung Group Holdings's Rubius Therapeutics, Inc position peaked at $1.39M in Q2 2021.
72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on Nan Fung Group Holdings's 13F filing for Q2 2022, filed 12 Aug 2022.